Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
We analyzed the effect of age on highly active antiretroviral therapy efficacy and tolerance in 639 patients with human immunodeficiency virus (HIV) infection (99 of whom were aged >50 years, and 540 of whom were aged <50 years). Late testing, which was more frequent in the older age group, was the only independent factor associated with immunologic and clinical evolution of infection. Age >50 years was associated with earlier treatment discontinuation.
Cuzin
Lise
L
Department of Infectious and Tropical Diseases, Hopital Purpan, Toulouse, France. cuzin.l@chu-toulouse.fr
Delpierre
Cyrille
C
Gerard
Stéphane
S
Massip
Patrice
P
Marchou
Bruno
B
D000328:Adult; D000367:Age Factors; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D044966:Anti-Retroviral Agents